Up 230% since its Q4 earnings in March, Virios Therapeutics, Inc. (NASDAQ: VIRI) showed tremendous progress in its Q1 earnings in May. The company not only reported an EPS loss less than half of estimates, successfully reducing its cash burn by almost 60% QoQ, but reported significant progress in preparing its IMC-1 treatment for Phase 3 trials. As a...
This looks like the beginning of a possible breakout after a volatility consolidation pattern.
Virios Therapeutics LLC (NASDAQ:VIRI) has been falling since the first trading day from over $16.5 to $6.45 and finally it seems to be bottoming. Last week broke the primary downtrend line on decent volume is now touching the $8 area resistance that it should be broken very soon. I have been accumulating this stock for a run to $10.80 at least. If you haven't...
Virios Therapeutics, LLC, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Innovative Med...